News
VTGN
2.600
+0.19%
0.005
VistaGen Therapeutics Advances Neurocircuitry Treatments
TipRanks · 1d ago
Weekly Report: what happened at VTGN last week (1125-1129)?
Weekly Report · 5d ago
Weekly Report: what happened at VTGN last week (1118-1122)?
Weekly Report · 11/25 09:00
Stifel Nicolaus Sticks to Their Buy Rating for VistaGen Therapeutics (VTGN)
TipRanks · 11/21 13:32
Weekly Report: what happened at VTGN last week (1111-1115)?
Weekly Report · 11/18 09:00
Weekly Report: what happened at VTGN last week (1104-1108)?
Weekly Report · 11/11 09:00
VistaGen Therapeutics’ Promising Clinical Progress and Strong Financial Position Justify Buy Rating
TipRanks · 11/09 15:35
Vistagen Therapeutics Reports Increased R&D Expenses
TipRanks · 11/08 05:43
Vistagen Therapeutics, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/08 01:53
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 11/08 00:30
VistaGen Therapeutics Q2 2025 GAAP EPS $(0.42) Misses $(0.39) Estimate, Sales $183.000K Miss $223.333K Estimate
Benzinga · 11/08 00:08
Vistagen reports Q2 EPS (42c), consensus (39c)
TipRanks · 11/07 21:32
VISTAGEN THERAPEUTICS INC - QTRLY SHR LOSS $0.42
Reuters · 11/07 21:20
Press Release: Vistagen Reports Fiscal Year 2025 -2-
Dow Jones · 11/07 21:20
Press Release: Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
Dow Jones · 11/07 21:20
Weekly Report: what happened at VTGN last week (1028-1101)?
Weekly Report · 11/04 09:00
Press Release: Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
Dow Jones · 11/01 12:31
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
NASDAQ · 10/30 12:05
Weekly Report: what happened at VTGN last week (1021-1025)?
Weekly Report · 10/28 09:00
Weekly Report: what happened at VTGN last week (1014-1018)?
Weekly Report · 10/21 09:00
More
Webull provides a variety of real-time VTGN stock news. You can receive the latest news about Vistagen Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VTGN
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.